INVESTORS
NEWSROOM
Responsibility
SUBSCRIBE
CONSUMERS
HEALTHCARE PROFESSIONALS
CAREERS
ABOUT ABBOTT
An Update on Abbott's Work on COVID-19 Testing
Abbott is continuing to ramp up production of our COVID-19 tests across our five platforms and ship to more customers in the U.S., helping healthcare providers on the front lines battle this pandemic.
Here's an update:
ID NOW – Our rapid, portable testing instrument used in urgent care clinics, hospital emergency departments, and physicians' offices
Molecular lab tests – Our high-volume molecular laboratory instruments to detect novel coronavirus
Antibody lab tests – Our lab-based antibody blood tests to help determine if a person was previously infected with the virus that causes COVID-19
Aug. 5, 2020
July 17, 2020
Abbott is continuing to ramp up production of our COVID-19 tests across our five platforms and ship to more customers, helping healthcare providers on the front lines battle this pandemic.
July 1, 2020
June 19, 2020
June 9, 2020
May 28, 2020
May 11, 2020
Today, Abbott gained EUA for our Alinity i COVID-19 antibody test and we continue to ramp up production of our COVID-19 tests across our four platforms and ship to more customers, helping healthcare providers on the front lines battle this pandemic.
m2000 – Our large, high-volume laboratory instrument
Antibody tests – Our lab-based antibody blood tests to help determine if a person was previously infected with the virus that causes COVID-19.
May 4, 2020
Abbott continues to expand accessibility to our COVID-19 tests by ramping up production and shipping to more customers, helping healthcare providers on the front lines.
Antibody test – Our lab-based antibody blood test that helps determine if a person was previously infected with the virus that causes COVID-19.
April 24, 2020
Antibody test – Last week, Abbott announced and began shipping a lab-based antibody blood test that helps determine if a person was previously infected with the virus that causes COVID-19.
April 15, 2020
Abbott launched its third COVID-19 test and will start shipping in the U.S.
Here are the details:
This new test is a serology test – also called an antibody test – and helps to detect the IgG antibody to SARS-CoV-2. Detecting these IgG antibodies will help determine if a person was previously infected with the virus that causes COVID-19.
April 13, 2020
Abbott has continued to expand accessibility to our COVID-19 tests by ramping up production and shipping to more customers, helping healthcare providers on the front lines.
Here’s an update:
April 3, 2020
We began distributing our rapid point-of-care COVID-19 tests for our ID NOW system on March 31. By the end of today we will have shipped more than 190,000 rapid tests to customers in 21 states. We're producing 50,000 tests every day now and we'll continue to ship daily to more customers in more places.
We're also continuing to ramp up our ID NOW manufacturing and plan to increase capacity to 2 million tests a month by June and are working to expand beyond that.
We've been in close coordination with U.S. federal and state authorities – as well as our customers in urgent care clinics, hospital emergency departments, and physicians' offices – to ensure ID NOW instruments and tests are sent to outbreak hotspots. While customers ultimately determine how our tests are deployed, we would like to prioritize frontline healthcare workers and first responders because we believe this is the best way to support the nation’s healthcare infrastructure.
Beyond delivering our tests, we are also doing all we can to monitor the deployment of the rapid tests and to avoid hoarding or price-gouging in secondary markets.
A rapid test is one part of the solution, not the only one. Our m2000 RealTime molecular laboratory instrument, for example, can run 470 tests a day and give results in about 6.5 hours. Importantly, we're now able to produce 1 million tests a week for our m2000 laboratory system. To date, we've shipped nearly 1 million tests to customers across the U.S. and have begun to ship tests to other countries around the world.
At Abbott, we have a saying, "we make our products as if they are for our own families." We and our families live in the same communities around the country and around the world that you do. We understand our responsibility. We know the stakes. We know 50,000 rapid tests a day are not enough. We can see the gaps also.
But we're not stopping here. We’re working 24/7 to make as many tests as we can and create the next round of needed tests. Our scientists continue to work on additional COVID-19 tests across the spectrum of our diagnostic instruments, including lateral flow and antibody tests. Our goal is to provide more testing, and to get our tests to more places around the world.
We're proud to be able to contribute in this fight and are committed for the duration.